Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 5/20 | 0.38 |
| ▸ | THRA | P10827 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239284 | 0.88 | ESR1 (0.38) | PLA2G2AALDH1A1GAAPOLBNPSR1 | |
| SCHEMBL5237418 | 0.88 | CNR2 (0.40) | PLA2G2AALDH1A1MEN1KMT2A | |
| SCHEMBL5233440 | 0.87 | L3MBTL1 (0.39) | PLA2G2AALDH1A1GAA | |
| SCHEMBL5238955 | 0.85 | PLA2G2A (0.38) | PLA2G2ATHRATHRBALDH1A1GAA | |
| Oxalic Acid SCHEMBL5576785 | 0.85 | KDM4E (0.46) | ALDH1A1GAAPOLBSMN1; SMN2MEN1 | |
| SCHEMBL5576340 | 0.84 | CCR2 (0.46) | ALDH1A1GAAPOLBNPSR1CCR2 | |
| SCHEMBL5233258 | 0.84 | MEN1 (0.38) | PLA2G2AALDH1A1GAAMEN1KMT2A | |
| SCHEMBL6109513 | 0.84 | RORA (0.40) | PLA2G2AALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5233361 | 0.84 | ALDH1A1 (0.46) | PLA2G2ATHRATHRBALDH1A1GAA | |
| SCHEMBL5235402 | 0.84 | PTGS1 (0.36) | GAAPOLBNPSR1CCR2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | PLA2G2A 3137/4885THRA 1886/4885THRB 1540/4885 |
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | PLA2G2A 4690/4885THRA 412/4885THRB 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.